Brought to you by 
The Medicines Co. gets rights to Alnylam's ALN-PCS program
16 Jan 2020
Executive Summary
The Medicines Co. (TMC) has licensed exclusive worldwide development, manufacturing, and commercialization rights to RNAi therapeutics firm Alnylam Pharmaceuticals Inc.’s ALN-PCS RNAi program for hypercholesterolemia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com